Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

@article{Barnett2004AngiotensinreceptorBV,
  title={Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.},
  author={Anthony H. Barnett and Stephen C. Bain and Paul K. Bouter and Bengt E. Karlberg and Sten Madsbad and Jak Jervell and Jukka Mustonen},
  journal={The New England journal of medicine},
  year={2004},
  volume={351 19},
  pages={
          1952-61
        }
}
BACKGROUND Few studies have directly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors in persons with type 2 diabetes. METHODS In this prospective, multicenter, double-blind, five-year study, we randomly assigned 250 subjects with type 2 diabetes and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg daily, in 120 subjects) or the ACE inhibitor enalapril (20 mg daily, in 130… Expand
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
TLDR
The data suggested that ARB, like ACE, treatment might slow the progression of renal dysfunction, and pointed to the necessity to be alerted to the progression to endstage renal disease with longterm medication. Expand
Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
TLDR
The combination of lisinopril and irbesartan was unable to show a benefit on the risk of progression of type 2 diabetic nephropathy, and there were no significant differences in proteinuria reduction or blood pressure control between groups. Expand
Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes.
TLDR
This study did not show significant differences between the classes in preventing renal function decline in DM2 patients in primary care. Expand
A Fiveyear Comparison of the Renal Protective Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with NonDiabeticNephropathy
TLDR
The data suggested that ARB, like ACE, treatment might slow the progression of renal dysfunction, and pointed to the necessity to be alerted to the progression to endstage renal disease with longterm medication. Expand
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
TLDR
The effects of ACE inhibitors and ARBs seem to be different, favouring the use of ARBs, and the need for a well-designed prospective study on type 2 diabetic patients with heavy proteinuria is warranted. Expand
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease
TLDR
This review summarized the results of the studies on the benefits of ARBs, ACEIs, and their combination in patients with diabetic nephropathy or cardiovascular diseases and demonstrated renoprotection with the use ofARBs compared with ACEIs. Expand
Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers for Prevention and Treatment of Nephropathy Associated with Type 2 Diabetes Mellitus
TLDR
Limited data suggest that combination therapy with ACE inhibitors and ARBs may slow the progression of microalbuminuria to clinical albuminuria. Expand
The Effects of Blocking Angiotensin Receptors on Early Stages of Diabetic Nephropathy
TLDR
Angiotensin receptor blockers may reduce VCAM-1 and microalbuminuria and may increase NO levels in early stages of DN. Expand
Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
TLDR
The addition of telmisartan to a maximum dose of ACEI is safe and results in further albuminuria decrease in patients with type 2 diabetes and incipient nephropathy. Expand
Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy
TLDR
For reimbursement and reference pricing decisions, there is a need for a head-to-head comparison of an ACE inhibitor with ARBs to model all possible costs and effects of ACE inhibitors and ARBs, where both types of drugs can be compared for healthcare decisions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
TLDR
Whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy is determined. Expand
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
TLDR
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone. Expand
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
TLDR
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes. Expand
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
TLDR
It is indicated that a one-year course of antihypertensive therapy with either losartan or enalapril significantly reduces UAE in hypertensive type 2 diabetic patients with early nephropathy. Expand
EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY
A BSTRACT Background Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin–angiotensin system slows the progression of renal disease in patients with type 1Expand
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
TLDR
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug. Expand
Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients
TLDR
A relatively long-term, 5-year study of the effect of the angiotensin-converting enzyme inhibitor, enalapril, on the course of diabetic nephropathy in normotensive, type II diabetic patients with microalbuminuria and normal renal function. Expand
Angiotensin-converting enzyme inhibitors.
TLDR
Ongoing studies will elucidate the effect of ACE inhibitor on cardiovascular mortality in essential hypertension, the role of ACE inhibitors in patients without ventricular dysfunction after myocardial infarction, and the roleof ACE inhibitors compared with newly available angiotensin AT1 receptor antagonists. Expand
Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria.
The primary results of a three-year prospective, double-blind, placebo-controlled trial in non-insulin-dependent diabetic (NIDDM) patients show that an anti-hypertensive regimen, which includes theExpand
Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
The DETAIL (diabetics exposed to telmisartan and enalapril) study will compare the long-term renal outcome of treatment with the angiotensin II receptor antagonist (ARA) telmisartan versus theExpand
...
1
2
3
...